Soft Or Connective Tissue Sarcoma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for soft or connective tissue sarcoma. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
2
Active US patents
65/100
Avg vulnerability
—
Annual revenue covered

Originators in Soft Or Connective Tissue Sarcoma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Janssen Prods 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating soft or connective tissue sarcoma. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
28

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Yondelis
TRABECTEDIN
 Janssen Prods 2 65 — 2028-01-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8895557 Yondelis other 75 2028-07-07
8895557 Yondelis formulation 55 2028-01-07

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8895557 Yondelis formulation 55 2028-01-07
8895557 Yondelis other 75 2028-07-07

Related